Serious Health Threat of Mucormycosis During the Ongoing Covid-19 Pandemic: What Dermatologists Need to Know in This Regard Publisher Pubmed



Hatami P¹ ; Balighi K^{1, 2} ; Nicknam Asl H³ ; Aryanian Z^{1, 4}
Source: International Journal of Dermatology Published:2022

Abstract

Background: Recently, a surge of mucormycosis in patients affected with or recovered from SARS-Cov-2 has been noted, especially in developing countries such as India, Pakistan, and Iran. Aim: To focus on existing data about the important aspects of COVID-associated mucormycosis. Methods: We searched on PubMed, Google Scholar, and Scopus in this regard, and all of the relevant papers published until August 28, 2021, for which we could access their full-texts, were included. Results: We found some recommendations made by ophthalmologists, anesthesiologists, and ENT surgeons and tried to summarize them to provide a practical guide for dermatologists. Conclusion: Careful examination and clinical suspicion are the key factors for correct diagnosis especially in patients affected by or recently recovered from COVID. Implementing some preventive measures such as using a titrated dose of corticosteroids and encouraging patients to get vaccinated should be considered to tackling this serious issue. © 2022 the International Society of Dermatology.